or Try an Advanced Search...

    Technical Analysis for RENB - Renovaro Biosciences Inc.

    Grade Last Price % Change Price Change
    F 0.50 6.47% 0.03
    RENB closed up 6.47 percent on Wednesday, November 20, 2024, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical RENB trend table...
    Date Alert Name Type % Chg
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Up Strength 0.00%
    Oversold Stochastic Weakness 0.00%
    50 DMA Resistance Bearish 6.47%
    Outside Day Range Expansion 6.47%
    Wide Bands Range Expansion 6.47%
    Gapped Up Strength 6.47%
    Down 3 Days in a Row Weakness 6.47%
    Down 4 Days in a Row Weakness 6.47%
    Older End-of-Day Signals for RENB ...

       Recent Intraday Alerts

    Alert Time
    Gapped Up (Partial) about 22 hours ago
    Up 5% about 22 hours ago
    Up 3% about 22 hours ago
    Up 2% about 22 hours ago
    Up 1% about 22 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    RENB Chart by TradingView
    Basic chart:

    Profile

    Renovaro Biosciences Inc. Description

    Enochian Biosciences Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-DB-01, a therapeutic cancer vaccine for the long term maintenance and prevention of relapse for the treatment of stage III and IV colon cancer patients; ENOB-DC-11 Innovative DC vaccine for multiple solid tumors; and ENOB-DC-21 for intratumoral injection. The company has strategic partnerships with The Scripps Institute and Fred Hutchinson Cancer Center. Enochian BioSciences was incorporated in 2017 and is based in Los Angeles, California.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Cancer Solid Tumors Infectious Diseases Vaccines HIV Cancer Vaccine

    Is RENB a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 3 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 4 Renovaro Issues Shareholder Letter and Provides Corporate Update
    Oct 30 Renovaro files for $200M mixed securities shelf
    Oct 17 RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing
    Oct 16 Renovaro Announces Strategic Restructuring and Leadership Transition
    Sep 19 PersonalAIze and Cube Forge Groundbreaking Partnership to Accelerate AI-Driven Healthcare Platform and Point of Care Diagnostics
    Sep 17 Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection
    Sep 13 RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress
    Sep 11 RenovaroCube Announces Strategic Offering of Up to 20% Ownership
    Jul 31 Russell 2000 rise: Top 5 best, worst performers during July's rally in small-cap stocks
    Jul 26 The Junk in Your Index Fund Is Costing You Big-Time
    See more RENB news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.25
    52 Week Low 0.395
    Average Volume 492,309
    200-Day Moving Average 1.41
    50-Day Moving Average 0.55
    20-Day Moving Average 0.56
    10-Day Moving Average 0.56
    Average True Range 0.09
    RSI (14) 44.13
    ADX 25.13
    +DI 20.63
    -DI 14.85
    Chandelier Exit (Long, 3 ATRs) 0.46
    Chandelier Exit (Short, 3 ATRs) 0.72
    Upper Bollinger Bands 0.66
    Lower Bollinger Band 0.45
    Percent B (%b) 0.25
    BandWidth 37.11
    MACD Line -0.02
    MACD Signal Line 0.00
    MACD Histogram -0.0124
    Fundamentals Value
    Market Cap 33.87 Million
    Num Shares 67.2 Million
    EPS -0.71
    Price-to-Earnings (P/E) Ratio -0.71
    Price-to-Sales 0.00
    Price-to-Book 5.19
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.59
    Resistance 3 (R3) 0.59 0.57 0.57
    Resistance 2 (R2) 0.57 0.55 0.57 0.57
    Resistance 1 (R1) 0.54 0.53 0.55 0.53 0.56
    Pivot Point 0.51 0.51 0.52 0.51 0.51
    Support 1 (S1) 0.48 0.49 0.50 0.48 0.44
    Support 2 (S2) 0.46 0.48 0.46 0.44
    Support 3 (S3) 0.43 0.46 0.44
    Support 4 (S4) 0.42